| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Gideon Kersten | Q77086557 |
| Eva Gönczöl | Q86761237 | ||
| P2093 | author name string | Jennifer Warner | |
| Siri Mjaaland | |||
| Amanda Semper | |||
| Cécile van Els | |||
| Corine Kruiswijk | |||
| Fredrik Oftung | |||
| Jon Hansen | |||
| Jørgen de Jonge | |||
| Julia Sarkadi | |||
| Karen Smith Korsholm | |||
| Lisbeth Næss | |||
| P2860 | cites work | Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza | Q21091074 |
| Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells | Q21562507 | ||
| Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans | Q22255463 | ||
| Making better influenza virus vaccines? | Q22305647 | ||
| Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses | Q24649949 | ||
| Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population | Q24655857 | ||
| Antibody recognition of a highly conserved influenza virus epitope | Q24655932 | ||
| Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines | Q27013568 | ||
| Highly Conserved Protective Epitopes on Influenza B Viruses | Q27671404 | ||
| Receptor binding by an H7N9 influenza virus from humans | Q27684857 | ||
| Update on avian influenza A (H5N1) virus infection in humans | Q28264923 | ||
| Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice | Q28727930 | ||
| Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans | Q29616204 | ||
| T-cell quality in memory and protection: implications for vaccine design | Q30014840 | ||
| Cell-mediated protection in influenza infection. | Q30353071 | ||
| Cellular immune correlates of protection against symptomatic pandemic influenza. | Q30353819 | ||
| Mucosal immunity and nasal influenza vaccination | Q38028996 | ||
| Immunological assessment of influenza vaccines and immune correlates of protection | Q38105339 | ||
| Clearance of influenza virus infections by T cells: risk of collateral damage? | Q38110656 | ||
| Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults | Q39744811 | ||
| Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. | Q39770621 | ||
| DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial | Q40392276 | ||
| Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens | Q42003390 | ||
| The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses | Q42790878 | ||
| Immune correlates of protection against influenza: challenges for licensure of seasonal and pandemic influenza vaccines, Miami, FL, USA, March 1-3, 2010. | Q43186538 | ||
| Granzyme B: a marker of risk for influenza in institutionalized older adults | Q43631933 | ||
| Initial infectious dose dictates the innate, adaptive, and memory responses to influenza in the respiratory tract | Q43638860 | ||
| Universal influenza vaccine: the holy grail? | Q43692141 | ||
| Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children | Q43963300 | ||
| Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design | Q44133304 | ||
| Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans | Q44168559 | ||
| Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24-26 January 2013. | Q44197848 | ||
| Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response | Q44237462 | ||
| The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination | Q44311458 | ||
| Association of serum anti-neuraminidase antibody with resistance to influenza in man. | Q44693807 | ||
| Influenza virus-like particles as a new tool for vaccine immunogenicity testing: validation of a neuraminidase neutralizing antibody assay | Q45368082 | ||
| Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys | Q45387290 | ||
| Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines | Q45733411 | ||
| Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine | Q45743764 | ||
| Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates | Q46147530 | ||
| Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity | Q47725631 | ||
| Immune correlates of protection against influenza in the human challenge model. | Q47752415 | ||
| Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. | Q49079509 | ||
| Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. | Q51671780 | ||
| Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus | Q37207762 | ||
| Development and preclinical evaluation of an alphavirus replicon vaccine for influenza | Q37252749 | ||
| Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test. | Q37331633 | ||
| Seasonal influenza vaccines: evolutions and future trends | Q37434517 | ||
| Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response | Q37461377 | ||
| Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability | Q37478325 | ||
| Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults | Q37530383 | ||
| Animal models for evaluation of influenza vaccines. | Q37600679 | ||
| A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses | Q37626927 | ||
| A universal influenza vaccine: where are we in the pursuit of this "Holy Grail"? | Q37834199 | ||
| Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations | Q37857257 | ||
| Correlates of vaccine protection from influenza and its complications | Q37976539 | ||
| New technologies for new influenza vaccines. | Q38009579 | ||
| The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice. | Q52007733 | ||
| Cloning, expression and immunoassay detection of ferret IFN-gamma. | Q53499287 | ||
| Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. | Q53892487 | ||
| Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). | Q54361083 | ||
| FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10–11, 2007 | Q54691178 | ||
| Live attenuated versus inactivated influenza vaccine in infants and young children. | Q55043222 | ||
| Cytotoxic T-cell immunity to influenza. | Q55062679 | ||
| Standardization and validation of assays determining cellular immune responses against influenza | Q63880645 | ||
| Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets | Q64379999 | ||
| The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells | Q74286639 | ||
| T cell responses are better correlates of vaccine protection in the elderly | Q83276474 | ||
| Characterization of antibodies against ferret immunoglobulins, cytokines and CD markers | Q84021714 | ||
| Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial | Q84104357 | ||
| Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences | Q84557620 | ||
| Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial | Q84747835 | ||
| DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials | Q85047234 | ||
| Oil-in-water emulsion adjuvant with influenza vaccine in young children | Q85087747 | ||
| Reproducibility of assays for influenza vaccine immunogenicity determination: progress towards consistency | Q87357535 | ||
| Effect of neuraminidase antibody on Hong Kong influenza | Q93737304 | ||
| Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. | Q30358843 | ||
| Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. | Q30359842 | ||
| Animal models in influenza vaccine testing. | Q30371058 | ||
| Correlates of protection: novel generations of influenza vaccines. | Q30375051 | ||
| Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. | Q30375991 | ||
| Animal models for the preclinical evaluation of candidate influenza vaccines. | Q30383623 | ||
| Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. | Q30385089 | ||
| Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine | Q30388038 | ||
| Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus | Q30389157 | ||
| Needle-free influenza vaccination. | Q30394326 | ||
| Development and evaluation of an M2-293FT cell-based flow cytometric assay for quantification of antibody response to native form of matrix protein 2 of influenza A viruses | Q30402664 | ||
| Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells | Q30403572 | ||
| Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model | Q30403760 | ||
| Registration of influenza vaccines for children in Europe | Q30405717 | ||
| Immune responses to influenza virus infection | Q30407654 | ||
| Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines | Q30408295 | ||
| Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis | Q30408691 | ||
| Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza | Q30410241 | ||
| Role of T cell immunity in recovery from influenza virus infection | Q30411514 | ||
| New technologies for influenza vaccines | Q30411859 | ||
| Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans | Q30412301 | ||
| Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine | Q30412800 | ||
| Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model | Q30414135 | ||
| T-helper 1 cells elicited by H5N1 vaccination predict seroprotection | Q30416272 | ||
| Advances in the development of universal influenza vaccines | Q30421502 | ||
| Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge | Q30421687 | ||
| The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus | Q30423530 | ||
| The consortium for the standardization of influenza seroepidemiology (CONSISE): a global partnership to standardize influenza seroepidemiology and develop influenza investigation protocols to inform public health policy | Q30425378 | ||
| Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase | Q30425783 | ||
| H5N1 pathogenesis studies in mammalian models | Q30427806 | ||
| Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines | Q30540603 | ||
| Climate and vectorborne diseases | Q33377739 | ||
| Climate change and infectious diseases in Europe | Q33452300 | ||
| Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults | Q33567685 | ||
| Hospital outbreak of Middle East respiratory syndrome coronavirus | Q33642332 | ||
| A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects | Q33782762 | ||
| Pathogenesis of Influenza A/H5N1 virus infection in ferrets differs between intranasal and intratracheal routes of inoculation | Q33922699 | ||
| Influenza virus vaccine based on the conserved hemagglutinin stalk domain | Q34030587 | ||
| Influenza Vaccines for the Future | Q34150283 | ||
| Clinical and immunologic predictors of influenza illness among vaccinated older adults | Q34170212 | ||
| Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity | Q34629133 | ||
| Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. | Q34699088 | ||
| Influenza vaccine responses in older adults | Q34705027 | ||
| Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease | Q34976021 | ||
| Systems biology of vaccination for seasonal influenza in humans | Q35118722 | ||
| Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children | Q35167127 | ||
| Targeting B cell responses in universal influenza vaccine design | Q35540405 | ||
| Haemagglutination-inhibiting antibody to influenza virus | Q35747515 | ||
| Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies | Q35833488 | ||
| Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans | Q36014866 | ||
| Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG | Q36349746 | ||
| Mucosal vaccines: the promise and the challenge | Q36402244 | ||
| Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach | Q36445635 | ||
| Sublingual vaccination with influenza virus protects mice against lethal viral infection | Q36446440 | ||
| Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines | Q36462309 | ||
| Localized mucosal response to intranasal live attenuated influenza vaccine in adults | Q36606611 | ||
| Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study | Q36621905 | ||
| Induction of secretory immunity and memory at mucosal surfaces | Q36709727 | ||
| Screening monoclonal antibodies for cross-reactivity in the ferret model of influenza infection | Q36746844 | ||
| Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children | Q36746934 | ||
| Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination | Q36752092 | ||
| An altered relationship of influenza vaccine-specific IgG responses with T cell immunity occurs with aging in humans | Q36789241 | ||
| Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use. | Q36861572 | ||
| Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies | Q36911722 | ||
| Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels | Q37106916 | ||
| Expanding roles for CD4⁺ T cells in immunity to viruses. | Q37150560 | ||
| Vaccines: correlates of vaccine-induced immunity | Q37193062 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine engineering | Q14861085 |
| P304 | page(s) | 1935-1948 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Fast vaccine design and development based on correlates of protection (COPs). | |
| P478 | volume | 10 |
| Q30403003 | Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers |
| Q89001788 | Antibodies and tuberculosis: finally coming of age? |
| Q59350720 | Defining a correlate of protection for chikungunya virus vaccines |
| Q38510148 | Development of cross-protective influenza a vaccines based on cellular responses |
| Q90621797 | Distinguishing Causation from Correlation in the Use of Correlates of Protection to Evaluate and Develop Influenza Vaccines |
| Q30385397 | Influenza immunology evaluation and correlates of protection: a focus on vaccines. |
| Q94602401 | Malaria vaccines: facing unknowns |
| Q30372521 | Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial. |
| Q40069663 | Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: blind, randomized and placebo-controlled trial |
| Q89944324 | The Kaposi's Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals |
| Q91449694 | Updates on immunologic correlates of vaccine-induced protection |
Search more.